Neurocrine Biosciences
NBIX
NBIX
231 hedge funds and large institutions have $3.86B invested in Neurocrine Biosciences in 2016 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 67 increasing their positions, 96 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
30% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 96
Holders
231
Holding in Top 10
7
Calls
$82.9M
Puts
$13.9M
Top Buyers
| 1 | +$43.5M | |
| 2 | +$38.6M | |
| 3 | +$33.6M | |
| 4 |
JP Morgan Chase
New York
|
+$26.8M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$25.5M |
Top Sellers
| 1 | -$84.2M | |
| 2 | -$58.1M | |
| 3 | -$39.9M | |
| 4 |
O
OrbiMed
New York
|
-$38.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$35.4M |